11/25/2022  5:31:15 PM Chg. +0.020 Volume Bid6:45:24 PM Ask6:45:24 PM Market Capitalization Dividend Y. P/E Ratio
6.310CHF +0.32% 29,266
Turnover: 184,263.115
6.350Bid Size: 200 6.450Ask Size: 50 203.77 mill.CHF 0.00% -

Business description

Molecular Partners AG is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Management board & Supervisory board

Dr. Patrick Amstutz
Management board
Andreas Emmenegger, Alexander Zürcher, Dr. Ana Maria Mendes Cerdeira, Dr. Daniel Steiner, Dr. Julia Hepp, Dr. Michael Tobias Stumpp, Julien Gander, Nicolas Leupin, M.D., Robert Hendriks, Seth Lewis
Supervisory board
William Burns, Dominik Höchli, M.D., Dr. Agnete Fredriksen, Dr. Michal Vasconelles, Dr. Patrick Amstutz, Dr. Vito L. Palombella, Sandip Kapadia, Steven H. Holtzman

Company data

Name: Molecular Partners AG
Address: Wagistrasse 14,CH-8952 Zürich-Schlieren
Phone: +41-44-755-7700
Fax: +41-44-755-7707
E-mail: -
Internet: www.molecularpartners.com
Industry: Biotechnology
Sector: Biotechnology
Sub sector: Biotechnology
End of financial year: 12/31
Free Float: 58.15%
IPO date: -

Investor relations

Name: Seth Lewis
IR phone: +41-44-755-5728
IR Fax: -
IR e-mail: seth.lewis@molecular...ers.com seth.lewis@molecularpartners.com

Company calendar

CW 10 | 3/9/2023 4th Quarter/Annual Report
CW 14 | 4/4/2023 General Shareholder Meeting

Main Shareholders

Mark N. Lampert (Biotechnology Value Funds)
Hansjoerg Wyss
Suvretta Capital Management, LLC
Novartis AG
Federated Hermes, Inc.
Essex Woodlands Health Ventures VIII, LLC
UBS Fund Management (Switzerland) AG